Delivering Disease-Modifying Therapy in T1D

Target Audience

The educational design of this activity addresses the needs of endocrinology and diabetology MDs, NPs, PAs, diabetes educators, and nurses, as well as infusion center nurses who are positioned to initiate teplizumab and manage the clinical workflows associated with disease-modifying therapy.

Program Overview

There are now multiple recognized stages of type 1 diabetes (T1D), each defined by the presence of autoantibodies and glycemic levels. Endocrinologists play a significant role in determining disease stage and assessing eligibility for teplizumab to slow T1D progression. If a patient is eligible, infusion center staff must be prepared to administer therapy, monitor patients, and mitigate adverse events. Endocrinologists must also be prepared to educate patients and families about T1D and available approaches to slow disease progression. In this interactive activity featuring both videos and transcripts, Dr. Emily Sims will present key considerations related to T1D autoantibody testing, clinical data informing eligibility for teplizumab, strategies to streamline workflow for medication administration, and patient and family education.

Educational Objectives

After completing this activity, the participant should be better able to:

• Develop or hone protocols for employing T1D autoantibody screening
• Assess patient eligibility for immunotherapy to delay T1D progression based on disease stage and clinical characteristics, within a shared decision-making framework
• Utilize immunotherapies to delay T1D progression, following clinic protocols and recommendations for patient eligibility and infusion protocols

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hour, including 0.0 pharmacotherapeutic contact hours, is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Certified Diabetes Care and Education Specialists

This continuing education activity was developed by Integritas Communications and its educational partners at Global Education Group. ADCES conducted an independent content review and found the content to be relevant and appropriate for diabetes care and education specialists.

Integritas Contact Information

For more information about the accreditation (ACCME and CDCES credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

To receive credit for this activity, participants must successfully pass the posttest with a score of 70% and complete the evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas and Global adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Emily K. Sims, MD, MS: Consulting Fees: Sanofi US, Diamyd Medical; Contracted Research: Sanofi US

The planners and managers at Integritas and Global have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas and Global do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.